Bharat Biotech starts clinical trials for TB vaccine
Hyderabad: Clinical trials for the new tuberculosis vaccine MTBVAC started in India on Sunday, a press release from Bharat Biotech said.

This is being viewed as a major leap in the battle against one of the deadliest infectious diseases globally, claiming over 1.6 million lives annually.
Developed through a collaboration between Spanish biopharmaceutical company Biofabri and Bharat Biotech, headquartered in Hyderabad, MTBVAC is derived from a strain of Mycobacterium tuberculosis found in humans, according to the release.
It holds potential as a more efficient and long-term alternative to the current tuberculosis vaccine, BCG, administered to newborns, which has been in use for over a century.
The BCG vaccine provides limited protection against pulmonary TB, the most prevalent and contagious form of the illness.
The trials aimed at examining the safety and immune response of MTBVAC have begun, with a crucial safety, immune response, and effectiveness trial scheduled to begin in 2025, as per the announcement.
Testing MTBVAC in adults and adolescents in a country where 28 percent of the world's tuberculosis cases are concentrated marks a big stride forward.
Before the clinical trials in India, the MTBVAC vaccine passed several critical milestones.
Following the recent conclusion of a Phase-2 trial to determine the optimal dosage, a double-blind controlled Phase-3 clinical trial in newborns commenced in 2023.
This trial aims to compare the efficacy of the MTBVAC vaccine with the existing BCG vaccine.
TB remains one of the world's top infectious causes of death, particularly in India, Esteban Rodriguez, CEO of Biofabri said.
Krishna Ella, Executive Chairman of Bharat Biotech said "Our quest for a more effective vaccine against Tuberculosis received a big boost today, with clinical trials in India. Our goal to develop TB vaccines to prevent disease in adults and adolescents has taken a big step today."
As many as 7,000 newborns from South Africa, 60 from Madagascar and 60 from Senegal will be vaccinated. To date, more than 1,900 babies have been vaccinated, the release added.
IBNS
Senior Staff Reporter at Northeast Herald, covering news from Tripura and Northeast India.
Related Articles

Delhi awaits rain after cloud-seeding trial to curb severe air pollution
The cloud-seeding trial aimed at inducing rainfall in pollution-hit Delhi has been completed, officials said on Monday, as the national capital continues to struggle with a thick blanket of toxic smog.

Hurricane Melissa: US Air Force flies into eye of storm, collects data
The 53rd Weather Reconnaissance Squadron of the United States Air Force conducted a daring mission into Hurricane Melissa, as it moved towards Jamaica, capturing footage inside the storm, termed as one of the most powerful to hit the region this year.

Cyclone Montha to make landfall today, Odisha, Andhra Pradesh on alert
The evacuation process has been heightened across Odisha and Andhra Pradesh with Cyclonic Storm “Montha” moving towards the coast and likely to make landfall between Kakinada between Machilipatnam and Kalingapatnam on Tuesday evening.

Vijaya Diagnostic Centre inaugurates State-of-the-Art Centre featuring first advanced 3 Tesla MRI in Kolkata
Kolkata/IBNS: Vijaya Diagnostic Centre, India’s largest B2C-focused integrated diagnostic chain, on Thursday announced the grand opening of its state-of-the-art diagnostic centre in Kasba, Kolkata.
Latest News

AI and Internet should be used for people’s welfare: CM

Bharat Scouts & Guides rendered voluntary services at stations during Chhath Puja

Delhi awaits rain after cloud-seeding trial to curb severe air pollution

Hurricane Melissa: US Air Force flies into eye of storm, collects data

